A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 701–800 of 1,008
Lehnert, S., Hartmann, S., Hessler, S., Adelsberger, H., Huth, T., & Alzheimer, C. (2016) · Channels · doi:10.1080/19336950.2016.1196307 · Cited by 33
“Nevertheless, the importance of BACE1 in AD pathogenesis has been demonstrated by mutations in APP, which either promote b-site cleavage causing a familial form of early-onset AD, or, contrarily, hinder APP b-cleavage and thus protect against the disease and even mild cognitive impairment.(23,24) As a note of caution…”
BackgroundMurray, B., Sorci, M., Rosenthal, J., Lippens, J. L., Isaacson, D., Das, P., Fabris, D., Li, S., & Belfort, G. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24995 · Cited by 38
Real-time nanoscale organization of amyloid precursor protein
Kedia, S., Ramakrishna, P., Netrakanti, P. R., Jose, M., Sibarita, J., Nadkarni, S., & Nair, D. K. (2020) · Nanoscale · doi:10.1039/d0nr00052c · Cited by 36
Satir, T. M., Agholme, L., Karlsson, A., Karlsson, M., Karila, P., Illes, S., Bergström, P., & Zetterberg, H. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00635-0 · Cited by 33
Why therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 39
Estrada, M., Pérez, C., Soriano, E., Laurini, E., Romano, M., Pricl, S., Morales-Garcia, J. A., Pérez‐Castillo, A., & Rodríguez-Franco, M. I. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0036 · Cited by 36
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity
Johansson, P., Kaspersson, K., Gurrell, I. K., Bäck, E., Eketjäll, S., Scott, C. W., Cebers, G., Thorne, P. V., McKenzie, M. J., Beaton, H. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01716 · Cited by 33
ADAM10 Prodomain Mutations Cause Late-Onset Alzheimer’s Disease: Not Just the Latest FAD
Vassar, R. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.031 · Cited by 32
“Importantly, a novel missense mutation that protects against AD by reducing total Ab generation was recently discovered in APP (Jonsson et al., 2012), thus underscoring the critical role of Ab in the pathophysiology of AD.”
BackgroundKunkle, B. W., Jaworski, J., Barral, S., Vardarajan, B., Beecham, G. W., Martin, E. R., Cantwell, L. S., Partch, A., Bird, T. D., Raskind, W. H., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.020 · Cited by 32
Hanson, J. E., Paré, J., Deng, L., Smith, Y., & Zhou, Q. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.017 · Cited by 35
Thakker, D. R., Sankaranarayanan, S., Weatherspoon, M. R., Harrison, J., Pierdomenico, M., Heisel, J. M., Thompson, L. A., Haskell, R., Grace, J. E., Taylor, S. J., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2262-14.2015 · Cited by 33
“…promising drug target, since mutations of the amyloid precursor protein (APP) that increase its cleavage by BACE1 increase the risk for AD, while others that inhibit cleavage by BACE1 significantly reduce the risk for AD and age-related cognitive decline (Vassar et al., 2009; Jonsson et al., 2012).”
BackgroundLin, T.-W., Chang, C., Chang, Y., Liao, Y., Yu, H., & Chen, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174561 · Cited by 37
Elucidating the Effect of Static Electric Field on Amyloid Beta 1–42 Supramolecular Assembly
Muscat, S., Stojceski, F., & Danani, A. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107535 · Cited by 32
Good Cop, Bad Cop: Defining the Roles of Δ40p53 in Cancer and Aging
Reinhardt, L. S., Zhang, X., Wawruszak, A., Groen, K., Iuliis, G. N. D., & Avery‐Kiejda, K. A. (2020) · Cancers · doi:10.3390/cancers12061659 · Cited by 37
The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review
Le, W., Yang, C., Yang, Q., Xiang, Y., Zeng, X., & Xiao, J. F. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343897 · Cited by 35
New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics
Lutz, M. W., Crenshaw, D. G., Welsh-Bohmer, K. A., Burns, D. K., & Roses, A. D. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0643-8 · Cited by 34
Genetic Analyses of Alzheimer’s Disease in China: Achievements and Perspectives
Zhang, D., Xu, M., Bi, R., & Yao, Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00435 · Cited by 33
Vassar, R. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.3 · Cited by 31
Peng, Y., Tao, H., Wang, S., Xiao, J., Wang, Y., & Su, H. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104463 · Cited by 31
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
“The Icelandic mutation (A673T mutation) is the only protective AD mutation that markedly decreases AD occurrence and significantly lowers the binding affinity of A β oligomers at synaptic receptors (Jonsson et al., 2012; Limegrover et al., 2020; Izzo et al., 2021).”
BackgroundCheng, Y., Brown, J., Judd, T. C., Lopez, P. L. D. C., Qian, W., Powers, T. S., Chen, J. J., Bartberger, M. D., Chen, K., Dunn, R. T., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500458t · Cited by 32
Leibing, A. (2014) · Culture Medicine and Psychiatry · doi:10.1007/s11013-014-9370-2 · Cited by 41
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 39
“Protective APP allele 25%↓ production Cell culture [8]”
BackgroundAyers, K. L., Mirshahi, U. L., Wardeh, A. H., Murray, M. F., Hao, K., Glicksberg, B. S., Li, S., Carey, D. J., & Chen, R. (2016) · BMC Genomics · doi:10.1186/s12864-016-2725-z · Cited by 33
“The most notable example is the APP A673T mutation protecting against AD as well as cognitive decline in the elderly without AD due to 40 % reduction in the formation of Aβ peptides [19].”
BackgroundChakraborty, S., & Das, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-10212-5 · Cited by 32
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)
Rombouts, F. J. R., Kusakabe, K., Hsiao, C., & Gijsen, H. J. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1832463 · Cited by 31
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
McKinzie, D. L., Winneroski, L. L., Green, S. J., Hembre, E. J., Erickson, J. A., Willis, B. A., Monk, S. A., Aluise, C. D., Baker, T. K., López, J. E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00489 · Cited by 33
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 33
“671 and aspartic acid 672) [532].”
Advantageous Uses of Mass Spectrometry for the Quantification of Proteins
Hale, J. E. (2013) · International Journal of Proteomics · doi:10.1155/2013/219452 · Cited by 41
“e association of A-beta with Alzheimer’s disease (AD) is well known [34], and its role as a causative agent has recently been strengthened [35].”
BackgroundLong-Term Oral Administration of Hop Flower Extracts Mitigates Alzheimer Phenotypes in Mice
Sasaoka, N., Sakamoto, M., Kanemori, S., Kan, M., Tsukano, C., Takemoto, Y., & Kakizuka, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087185 · Cited by 34
“The study identified an AD-resistant mutation (A673T) in APP near the b cleavage site [20].”
BackgroundInfluentialLamotrigine Reduces β-Site AβPP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy
Wu, H., Lu, M., Wang, W., Zhang, M., Zhu, Q.-Q., Xia, Y., Xu, R., Yang, Y., Chen, L., & Ma, Q. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143162 · Cited by 33
“A recently discovered A673T A PP mutation that makes the cleavage of A PP by BACE1 less efficient shows reduced A levels and cognitive benefit [9], further strengthening the idea that inhibition of BACE1 is a potential therapeutic target”
Wu, Y., Guernon, J. M., Yang, F., Snyder, L. B., Shi, J., McClure, A. C., Rajamani, R., Park, H., Ng, A., Lewis, H. A., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00432 · Cited by 33
Fleck, D., Phu, L., Verschueren, E., Hinkle, T. B., Reichelt, M., Bhangale, T., Haley, B., Wang, Y., Graham, R., Kirkpatrick, D. S., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0116-19.2019 · Cited by 31
“The concentration of A 40 peptides in the supernatant of primary neuron cultures was measured by sandwich ELISA as described previously (Jonsson et al., 2012): a rabbit polyclonal antibody specific for the A 40 C-terminus (AB5737, Millipore) was coated onto ELISA plates and a biotinylated anti-A…”
MethodSelf-citationFurther insights into Alzheimer disease pathogenesis
Weiner, M. W. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.275 · Cited by 34
Leveraging human genetics to guide drug target discovery
Stitziel, N. O., & Kathiresan, S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.008 · Cited by 31
Post-Translational Modifications of BACE1 in Alzheimer's Disease
Wen, W., Li, P., Liu, P., Xu, S., Wang, F., & Huang, J. H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210121163224 · Cited by 36
“Similar studies in humans reported a rare mutation at the BACE1 cleavage site of APP [A673T] resulted in an approximately 40% reduction in the formation of Aβ production in Icelanders; and these people showed a significant reduction for Aβ aggregates, and five- to seven-fold reduced risk of developing AD, and greater…”
ResultAdvances in the identification of β-secretase inhibitors
Hamada, Y., & Kiso, Y. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.784267 · Cited by 30
A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease
Peters, K. R., Beattie, B. L., Feldman, H., & Illes, J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.12.001 · Cited by 38
“…and AD by Wan et al. (Wan et al., 2009) and of the novel single nucleotide polymorphism mutation in the APP gene (A673T) among Icelanders by others (Jonsson et al., 2012) suggest that reductions in Ab of less than 50% could have substantial benefits in delaying disease onset or progression,…”
Bridging the Gap between Statistical and Biological Epistasis in Alzheimer’s Disease
Ebbert, M., Ridge, P. G., & Kauwe, J. S. K. (2015) · BioMed Research International · doi:10.1155/2015/870123 · Cited by 37
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 35
Sequence variants affecting the genome-wide rate of germline microsatellite mutations
Kristmundsdóttir, S., Jónsson, H., Hardarson, M. T., Pálsson, G., Beyter, D., Eggertsson, H. P., Gylfason, A., Sveinbjörnsson, G., Holley, G., Stefánsson, Ó. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39547-6 · Cited by 34
Self-citationFluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
“Several lines of research support the role of BACE1 activity in the pathogenesis of AD including two studies that have reported allelic variations, that reduce BACE1 activity, are protective against AD (202, 203).”
BackgroundGüttler, B. H.-O., Cynis, H., Seifert, F., Ludwig, H., Porzel, A., & Schilling, S. (2013) · Amino Acids · doi:10.1007/s00726-012-1454-0 · Cited by 29
“These reports are accompanied by several epidemiological studies that point to a crucial influence of the sequence surrounding the b-secretase cleavage site for generation of the N-terminus of Ab (Haass et al. 1995; Di Fede et al. 2009; Jonsson et al. 2012).”
Fujimoto, K., Yoshida, S., Tadano, G., Asada, N., Fuchino, K., Suzuki, S., Matsuoka, E., Yamamoto, T., Yamamoto, S., Ando, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01858 · Cited by 30
Urban, A. S., Pavlov, K. V., Kamynina, A. V., Okhrimenko, I. S., Arseniev, A. S., & Bocharov, E. V. (2021) · Molecules · doi:10.3390/molecules26102897 · Cited by 34
“Another APP mutation, A673T in the immediate vicinity of the cleavage β-site, was also described, decreasing APP proteolysis by β-secretases and the likelihood of spontaneous AD development [89].”
Backgroundpara‐Sulfonatocalix[n]arenes Inhibit Amyloid β‐Peptide Fibrillation and Reduce Amyloid Cytotoxicity
Wang, Z., Tao, S.-P., Dong, X., & Sun, Y. P. (2016) · Chemistry - An Asian Journal · doi:10.1002/asia.201601461 · Cited by 29
Bursavich, M. G., Harrison, B. A., Acharya, R. A., Costa, D. E., Freeman, E. A., Hodgdon, H., Hrdlicka, L., Jin, H. Y., Kapadnis, S., Moffit, J. S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01620 · Cited by 29
Candidate gene analysis for Alzheimer's disease in adults with Down syndrome
Lee, J. H., Lee, A., Dang, L. T., Pang, D. I., Kisselev, S., Krinsky‐McHale, S. J., Zigman, W. B., Luchsinger, J. A., Silverman, W. P., Tycko, B., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.018 · Cited by 29
“Jonsson et al. (2012) reported that rs63750847, a rare Icelandic mutation with allele frequency <1%, protects against age-related cognitive losses, but this finding has not yet been confirmed in other independent studies.”
ResultIs It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“Thus, understanding of APP processing appears fundamental for the development of a therapeutic strategy aimed at reducing Aβ levels in AD patients [21-25].”
BackgroundGenius, J., Klafki, H., Benninghoff, J., Esselmann, H., & Wiltfang, J. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0362-3 · Cited by 31
“Most relevant for the amyloid cascade hypothesis is that the authors could demonstrate that the latter point mutation leads to a loss of function in that the endoproteolytic Ab peptide generation is reduced [30].”
BackgroundOvercoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
“The recent demonstration that a rare genetic variant, which alters the coding sequence of Ab and reduces Ab production, reduces the risk for developing AD provides a counterexample of a mutation that does not confer risk, but, rather, protection from AD (Jonsson et al. 2012).”
BackgroundOpposite Epigenetic Associations With Alcohol Use and Exercise Intervention
Chen, J., Hutchison, K. E., Bryan, A. D., Filbey, F. M., Calhoun, V. D., Claus, E. D., Lin, D., Sui, J., Du, Y., & Liu, J. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00594 · Cited by 30
“Amyloid beta precursor protein (APP), while frequently implicated in Alzheimer’s disease (AD) and relating to the formation of amyloid plaques (61, 62), may also interact with reelin and modulate synaptic plasticity (63–65).”
BackgroundBACE1 partial deletion induces synaptic plasticity deficit in adult mice
Lombardo, S., Chiacchiaretta, M., Tarr, A., Kim, W., Cao, T., Sigal, G., Rosahl, T. W., Xia, W., Haydon, P. G., Kennedy, M. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56329-7 · Cited by 29
Trambauer, J., Fukumori, A., & Steiner, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.01.011 · Cited by 31
The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer’s Disease
Xia, Q., Yang, X., Shi, J., Liu, Z., Peng, Y., Wang, W., Li, B., Zhao, Y., Xiao, J., Huang, L. F., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02385-y · Cited by 34
“Specifically, the mutation affects the catalytic turnover (Vmax) of APP rather than APP binding affinity (Km) for BACE1 [21, 32].”
BackgroundMethodInfluentialGenetics of Alzheimer’s disease
König, T., & Stögmann, E. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00819-9 · Cited by 37
Volloch, V., & Rits‐Volloch, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512246 · Cited by 31
Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer’s disease
Yokoyama, J. S., Bonham, L. W., Sears, R. L., Klein, E., Karydas, A., Kramer, J. H., Miller, B. L., & Coppola, G. (2015) · BMC Neurology · doi:10.1186/s12883-015-0304-6 · Cited by 28
“62% [15]) AD.”
Strategies for Imputing and Analyzing Rare Variants in Association Studies
Hoffmann, T. J., & Witte, J. S. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.07.006 · Cited by 35
“13% controls) [32].”
A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease
Izuo, N., Kasahara, C., Murakami, K., Kume, T., Maeda, M., Irie, K., Yokote, K., & Shimizu, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-11671-6 · Cited by 31
Identification of key regions and residues controlling Aβ folding and assembly
Hayden, E. Y., Hoi, K. K., Lopez, J., Inayathullah, M., Condron, M. M., & Teplow, D. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-10845-6 · Cited by 30
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2019) · doi:10.1101/19012021 · Cited by 28
Self-citationGenes, pathways and risk prediction in Alzheimer’s disease
Hardy, J., & Escott-Price, V. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz163 · Cited by 27
“Conversely, an APP mutation which reduces the flux through the β-secretase pathway reduces the risk of dementia (7).”
BackgroundAging and cognitive resilience: Molecular mechanisms as new potential therapeutic targets
Cordeiro, A., Gomes, C., Bicker, J., & Fortuna, A. C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104093 · Cited by 31
Cognitive resilience in Alzheimer’s disease: Mechanism and potential clinical intervention
Jia, B., Xu, Y., & Zhu, X. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102711 · Cited by 31
2012: A watershed year for Alzheimer's disease research
Grundman, M., DiBernardo, A., Raghavan, N., Krams, M., & Yuen, E. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0002-2 · Cited by 27
Spector‐Bagdady, K., Prince, A. E. R., Yu, J., & Appelbaum, P. S. (2018) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31608 · Cited by 27
“This means that genetic-specific clinical informed consent may not be required by the statutes for variants associated with positive health effects (e.g., A673T in the APP gene, which helps protect against Alzheimer’s disease [Jonsson et al., 2012]).”
BackgroundU1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease
Bai, B. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00075 · Cited by 28
“Mutations that lead to enhanced Aβ production or fibrillization accelerate the onset of AD (Citron et al., 1992; Nilsberth et al., 2001), and those inhibiting Aβ generation reduce the likelihood of AD development (Jonsson et al., 2012).”
BackgroundLei, M., Teo, J. D., Song, H., McEwen, H. P., Yup Lee, J., Couttas, T. A., Duncan, T., Chesworth, R., Bertz, J., Przybyla, M., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0524-19.2019 · Cited by 27
“An APP gene variant that impairs A generation and protects against AD has also been identified (Jonsson et al., 2012), strongly implicating A generation from APP in AD pathogenesis.”
BackgroundEdraki, N., Firuzi, O., Fatahi, Y., Mahdavi, M. R., Asadi, M., Emami, S., Divsalar, K., Miri, R., Iraji, A., Khoshneviszadeh, M., et al. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400322 · Cited by 28
From genetic discovery to future personalized health research
Palotie, A. V., Widén, E., & Ripatti, S. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.11.013 · Cited by 32
Self-citationHein, L. K., Apaja, P. M., Hattersley, K. J., Grose, R., Xie, J., Proud, C. G., & Sargeant, T. J. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.011 · Cited by 27
Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 28
“…mutation carriers, and the rate of Aβ clearance is reduced by 30% in sporadic AD patients (Mawuenyega et al., 2010; Potter et al., 2013), whereas a 30% lower Aβ production rate in carriers of the APP A673T variant results in protection from AD (Jonsson et al., 2012; Martiskainen et al., 2017).”
BackgroundWang, J., Fourriere, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 27
Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes
Delvaux, E., Bentley, K., Stubbs, V., Sabbagh, M., & Coleman, P. D. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.004 · Cited by 26
“…Alzheimer’s disease (Hardy and Selkoe, 2002; Walsh et al., 2005; Haass and Selkoe, 2007; Shankar et al., 2007; Palop and Mucke 2010; Lublin and Gandy, 2010; Shimada et al., 2011; Jonsson et al., 2012), and are also ubiquitously present in many tissues throughout the body (e.g. Roher et al., 2009).”
BackgroundA Brief Synopsis on the Genetics of Alzheimer’s Disease
Kamboh, M. I. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0155-8 · Cited by 26
Camargo, L. M., Zhang, X. D., Loerch, P., Caceres, R. M., Marine, S. D., Uva, P., Ferrer, M., Rinaldis, E. D., Stone, D. J., Majercak, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115369 · Cited by 26
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
Desikan, R. S., Rafii, M. S., Brewer, J. B., & Hess, C. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3644 · Cited by 29
Strooper, B. D., & Voet, T. (2012) · Nature · doi:10.1038/488038a · Cited by 29
Intraneuronal β‐amyloid and its interactions with proteins and subcellular organelles
Penke, B., Tóth, A. M., Földi, I., Szűcs, M., & Janáky, T. (2012) · Electrophoresis · doi:10.1002/elps.201200297 · Cited by 30
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
“Using this ELISA configuration, there was no detectable difference between the wt and A673T mutant proteins in initial rate of oligomer formation (linear regression for slope difference, p = .67, F = .195; Figure 1b).”
BackgroundInfluentialRombouts, F. J. R., Kusakabe, K., Alexander, R., Austin, N. E., Borghys, H., Cleyn, M. A. J. D., Dhuyvetter, D., Gijsen, H. J. M., Hrupka, B. J., Jacobs, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00935 · Cited by 27
Cui, J., Ait‐Ghezala, G., Sambamurti, K., Gao, F., Shen, Y., & Li, R. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-20.2021 · Cited by 30
Takasugi, N., Komai, M., Kaneshiro, N., Ikeda, A., Kamikubo, Y., & Uehara, T. (2023) · Cells · doi:10.3390/cells12030454 · Cited by 29
“Several mutations in APP suggest the significance of β1 cleavage, including a cleavagepromoting Swedish mutation (KM-2/-1NL) [16] and a cleavage-inhibiting and protective Icelandic mutation (A2T) in the vicinity of the β1 cleavage site [17] (Figure 3).”
BackgroundRole of microbial dysbiosis in the pathogenesis of Alzheimer's disease
Susmitha, G., & Kumar, R. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109478 · Cited by 28
AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease
Descamps, O., Spilman, P. R., Zhang, Q., Libeu, C. P., Poksay, K. S., Gorostiza, O. F., Campagna, J. J., Jagodzinska, B. M., Bredesen, D. E., & John, V. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130578 · Cited by 31
Ting, S. K. S., Chong, M.-S., Kandiah, N., Hameed, S., Tan, L., Au, W.-L., Prakash, K. M., Pavanni, R., Lee, T.-S., Foo, J.-N., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.012 · Cited by 26
Genomics in Neurological Disorders
Han, G., Sun, J., Wang, J., Bai, Z., Song, F., & Lei, H. (2014) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2014.07.002 · Cited by 32
“78 · 10 (7)) in a study with 1795 samples [37].”
Kokawa, A., Ishihara, S., Fujiwara, H., Nobuhara, M., Iwata, M., Ihara, Y., & Funamoto, S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0247-6 · Cited by 29
“Results Effect of the A673T mutation on C99 levels in cells The A673T mutation in APP reduced the release of sAPPβ [9].”
BackgroundResultInfluentialClassification of Big Data With Application to Imaging Genetics
Ulfarsson, M. O., Pálsson, F., Sigurðsson, J., & Sveinsson, J. R. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2015.2501814 · Cited by 28
“, Alzheimer’s disease [16], or a quantitative phenotype, e.”
BackgroundHashimoto, Y., Toyama, Y., Kusakari, S., Nawa, M., & Matsuoka, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698092 · Cited by 26
“The AD-protective mutation not only reduces the production of A (42) but also attenuates the APP-mediated intracellular death signal independently of the reduction of A (13).”
BackgroundNew Genes and New Insights from Old Genes: Update on Alzheimer Disease
Ringman, J. M., & Coppola, G. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429179.21977.a1 · Cited by 38
“The above-mentioned rare variant in APP (A673T) has been identified in an Icelandic cohort and has a protective role.(22) Finally, two recent reports indicated that rare variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene increase the risk for AD.”
BackgroundResultGleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage
Netzer, W. J., Bettayeb, K., Sinha, S. C., Flajolet, M., Greengard, P., & Bustos, V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620963114 · Cited by 29
“Recently, an APP mutation (APP-A673T) that protects against the development of AD and age-related cognitive decline was identified in the Icelandic population (7, 8).”
BackgroundUmeda, T., Kimura, T., Yoshida, K., Takao, K., Fujita, Y., Matsuyama, S., Sakai, A., Yamashita, M., Yamashita, Y., Ohnishi, K., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0461-5 · Cited by 27
“Interestingly, A673T mutation at the same position in APP shows protective effects against AD by reducing Aβ production and aggregation [7].”
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 30
New molecular approaches to Alzheimer's disease
Resta, C. D., & Ferrari, M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.010 · Cited by 30
A Mutation in DAOA Modifies the Age of Onset in PSEN1 E280A Alzheimer’s Disease
Vélez, J. I., Rivera, D., Mastronardi, C. A., Patel, H. R., Tobón, C., Villegas, A., Cai, Y., Easteal, S., Lopera, F., & Arcos-Burgos, M. (2016) · Neural Plasticity · doi:10.1155/2016/9760314 · Cited by 25
“%) in APP had a protective effect against AD in Icelanders [5], whilst a rare mutation in the Phospholipase D family member 3 (PLD3) gene segregates in two families with late-onset AD (LOAD) and doubles the risk of AD in European and African American cases/control samples [6], but this association failed to replicate…”
BackgroundHippocampal sclerosis: A review on current research status and its mechanisms
Zhao, T., Cui, X., Zhang, X., Zhao, M., Rastegar‐Kashkooli, Y., Wang, J., Li, Q., Jiang, C. Q., Li, N., Xing, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102716 · Cited by 28
Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials
Rafii, M. S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00740-6 · Cited by 26
“Moreover, the discovery of a mutation in the APP gene that results in diminished production of Aβ and is protective against the development of AD pathology and dementia, further supports the notion that AD can be solely driven by APP dysmetabolism, resulting in increased production of Aβ [25].”
Background
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.